Search

Rachel Ryznal

from Boston, MA
Get Report
Connected to:
Adrienne M Ryznar, 46Ann E Ryznar, 94Klaudia Ryznar, 27Dane R Ryzner, 37Jared E Ryzner, 41Victoria A Ryzner, 41Brian A Ryznic, 58Charles R Ryznic, 41Dolores A Ryzok, 84Glenn H Ryzuk, 65

Rachel Ryznal Phones & Addresses

  • Boston, MA
  • Somerville, MA
  • 177 Marlborough St APT 7, Boston, MA 02116

Work

Position: Administration/Managerial

Education

Degree: Associate degree or higher

Resumes

Resumes

Rachel Ryznal Photo 1

Director - Liquid Handling

View page
Location:
San Francisco, CA
Industry:
Biotechnology
Work:
Corning Incorporated since Jun 2011
Business Development Manager
Corning, Inc. Aug 2010 - Jun 2011
Product Line Manager
Alkermes 2003 - 2008
Research Engineer
Education:
Cornell University - S.C. Johnson Graduate School of Management 2008 - 2010
MBA Worcester Polytechnic Institute 1999 - 2003
BS, Biomedical Engineering
Skills:
Cross Functional Team Leadership
R&D
Product Marketing
Product Development
Biotechnology
Product Management
Project Management
Strategy
Competitive Analysis
Business Development
Leadership
Management
Business Strategy
Data Analysis
Strategic Planning
Marketing Strategy
Product Launch
Market Analysis
Languages:
English
Rachel Ryznal Photo 2

Research Engineer At Alkermes

View page
Position:
Research Engineer at Alkermes
Location:
Greater Boston Area
Industry:
Pharmaceuticals
Work:
Alkermes
Research Engineer
Education:
Worcester Polytechnic Institute 1999 - 2003

Publications

Us Patents

Pulmonary Pharmaceutical Formulations

View page
US Patent:
20090105201, Apr 23, 2009
Filed:
Aug 21, 2008
Appl. No.:
12/195878
Inventors:
Charles D. Blizzard - Westwood MA, US
Michael M. Lipp - Framingham MA, US
Kevin L. Ward - Cambridge MA, US
Rachel Ryznal - North Oxford MA, US
Daniel Leblanc - Wellesley MA, US
Mark Tracy - Arlington MA, US
Rebbeca Martin - Blacksburg VA, US
Assignee:
Alkermes, Inc. - Cambridge MA
International Classification:
A61K 31/58
A61P 11/06
US Classification:
514174
Abstract:
The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment.

Pulmonary Pharmaceutical Formulations

View page
US Patent:
20220296612, Sep 22, 2022
Filed:
Nov 4, 2021
Appl. No.:
17/519119
Inventors:
- Ardsley NY, US
Michael M. Lipp - Framingham MA, US
Kevin L. Ward - Arlington MA, US
Rachel Ryznal - North Oxford MA, US
Daniel LeBlanc - Wellesley MA, US
Mark A. Tracy - Arlington MA, US
Rebecca Martin - Blacksburg VA, US
International Classification:
A61K 31/58
A61K 9/00
A61K 9/16
A61K 45/06
A61K 31/13
A61K 47/36
A61K 38/29
Abstract:
The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment.

Pulmonary Pharmaceutical Formulations

View page
US Patent:
20160151393, Jun 2, 2016
Filed:
Dec 4, 2015
Appl. No.:
14/959684
Inventors:
- Chelsea MA, US
Michael M. Lipp - Framingham MA, US
Kevin L. Ward - Arlington MA, US
Rachel Ryznal - North Oxford MA, US
Daniel LeBlanc - Wellesley MA, US
Mark A. Tracy - Arlington MA, US
Rebecca Martin - Blacksburg VA, US
International Classification:
A61K 31/58
A61K 38/29
A61K 9/00
Abstract:
The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment.

Pulmonary Pharmaceutical Formulations

View page
US Patent:
20140148424, May 29, 2014
Filed:
Nov 19, 2013
Appl. No.:
14/084550
Inventors:
- Chelsea MA, US
Michael M. Lipp - Framingham MA, US
Kevin L. Ward - Arlington MA, US
Rachel Ryznal - North Oxford MA, US
Daniel Leblanc - Wellesley MA, US
Mark Tracy - Arlington MA, US
Rebecca Martin - Blacksburg VA, US
Assignee:
Civitas Therapeutics, Inc. - Chelsea MA
International Classification:
A61K 47/36
A61K 31/58
US Classification:
514174
Abstract:
The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment.
Control profile
Rachel Ryznal from Boston, MA Get Report